NCT04488705View on ClinicalTrials.gov

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

May 19, 2021

Study Completion Date

May 19, 2021

Conditions
Healthy
Interventions
DRUG

ETD002 - single dose

Single ascending doses of ETD002

DRUG

Placebo - single dose

Single doses of placebo

DRUG

ETD002 - 7 day repeat dose

Twice daily doses of ETD002 for 7 days

DRUG

Placebo - 7 day repeat dose

Twice daily doses of Placebo for 7 days

DRUG

ETD002 - 14 day repeat dose

Twice daily doses of ETD002 for 14 days

DRUG

Placebo - 14 day repeat dose

Twice daily doses of Placebo for 14 days

DRUG

Salbutamol

Twice daily doses of salbutamol for 3 days (Days 5, 6 \& 7)

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research, London

Sponsors
All Listed Sponsors
lead

Enterprise Therapeutics Ltd

INDUSTRY

NCT04488705 - A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects | Biotech Hunter | Biotech Hunter